Skip to main content

Peer Review reports

From: The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Original Submission
8 Jun 2022 Submitted Original manuscript
17 Aug 2022 Reviewed Reviewer Report - Michel Shamy
29 Sep 2022 Reviewed Reviewer Report
4 Nov 2022 Author responded Author comments - Nicolas Bruder
Resubmission - Version 2
4 Nov 2022 Submitted Manuscript version 2
2 Dec 2022 Editorially accepted
20 Dec 2022 Article published 10.1186/s12883-022-03002-8

You can find further information about peer review here.

Back to article page